Search

Your search keyword '"Pontiroli, Antonio E."' showing total 519 results
Start Over Author "Pontiroli, Antonio E."
519 results on '"Pontiroli, Antonio E."'

54. Severity of SARS-CoV-2 infection as a function of the interferon landscape across the respiratory tract of COVID-19 patients

Author

Sposito, Benedetta, primary, Broggi, Achille, additional, Pandolfi, Laura, additional, Crotta, Stefania, additional, Ferrarese, Roberto, additional, Sisti, Sofia, additional, Clementi, Nicola, additional, Ambrosi, Alessandro, additional, Liu, Enju, additional, Frangipane, Vanessa, additional, Saracino, Laura, additional, Marongiu, Laura, additional, Facchini, Fabio A, additional, Bottazzi, Andrea, additional, Fossali, Tommaso, additional, Colombo, Riccardo, additional, Clementi, Massimo, additional, Tagliabue, Elena, additional, Pontiroli, Antonio E, additional, Meloni, Federica, additional, Wack, Andreas, additional, Mancini, Nicasio, additional, and Zanoni, Ivan, additional

Published
2021
Full Text
View/download PDF

65. Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders

Author

Barbanti, Francesca Alessandra, primary, Trento, Marina, additional, Bruno, Graziella, additional, Bonadonna, Riccardo, additional, Croci, Marina, additional, D’Eusebio, Chiara, additional, Dei Cas, Alessandra, additional, Invitti, Cecilia, additional, Merlo, Fabio, additional, Pontiroli, Antonio E., additional, Veronelli, Anna, additional, Vigili de Kreutzenberg, Saula, additional, Marchesini, Giulio, additional, and Petroni, Maria Letizia, additional

Published
2020
Full Text
View/download PDF

66. Bariatric surgery, compared to medical treatment, reduces morbidity at all ages but does not reduce mortality in patients aged < 43 years, especially if diabetes mellitus is present: a post hoc analysis of two retrospective cohort studies

Author

Pontiroli, Antonio E., primary, Ceriani, Valerio, additional, Tagliabue, Elena, additional, Zakaria, Ahmed S., additional, Veronelli, Annamaria, additional, Folli, Franco, additional, and Zanoni, Ivan, additional

Published
2019
Full Text
View/download PDF

79. The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes

Author

D'Adamo, Monica, Perego, Lucia, Cardellini, Marina, Marini, Maria Adelaide, Frontoni, Simona, Andreozzi, Francesco, Sciacqua, Angela, Lauro, Davide, Sbraccia, Paolo, Federici, Massimo, Paganelli, Michele, Pontiroli, Antonio E., Lauro, Renato, Perticone, Francesco, Folli, Franco, and Sesti, Giorgio

Subjects
Hyperglycemia -- Care and treatment, Insulin resistance -- Research, Insulin -- Health aspects, Insulin -- Research, Type 2 diabetes -- Care and treatment, Type 2 diabetes -- Research, Health
Abstract

Uncoupling protein (UCP)-2 is a member of the mitochondrial inner membrane carriers that uncouple proton entry in the mitochondrial matrix from ATP synthesis. The -866G/A polymorphism in the UCP2 gene, which enhances its transcriptional activity, was associated with enhanced risk for type 2 diabetes in obese subjects. We addressed the question of whether the -866G/A polymorphism contributes to variation in insulin sensitivity by genotyping 181 nondiabetic offspring of type 2 diabetic patients. Insulin sensitivity, assessed by the hyperinsulinemic-euglycemic clamp, was reduced in -866A/A carriers compared with -866A/G or -866G/G carriers (P = 0.01). To directly investigate the correlation between UCP2 expression and insulin resistance, UCP2 mRNA levels were measured by real-time RT-PCR in subcutaneous fat obtained from 100 obese subjects who underwent laparoscopic adjustable gastric banding. UCP2 mRNA expression was significantly correlated with insulin resistance as assessed by the homeostasis model assessment index (r = 0.27, P = 0.007). We examined the association of the -866A/A genotype in a case-control study including 483 type 2 diabetic subjects and 565 control subjects. The -866A/A genotype was associated with diabetes in women (odds ratio 1.84, 95% CI 1.03-3.28; P = 0.037), but not in men. These results indicate that the -866A/A genotype of the UCP2 gene may contribute to diabetes susceptibility by affecting insulin sensitivity., The pathophysiology of type 2 diabetes includes two apparently distinct defects, i.e., impairments in insulin action at the level of skeletal muscle, fat, and liver and inadequate compensation by the [...]

Published
2004

82. High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans: A Potential Role for Regulation of Specific Bcl Family Genes Toward an Apoptotic Cell Death Program

Author

Federici, Massimo, Hribal, Marta, Perego, Lucia, Ranalli, Marco, Caradonna, Zaira, Perego, Carla, Usellini, Luciana, Nano, Rita, Bonini, Paolo, Bertuzzi, Federico, Marlier, Lionel N.J.L., Davalli, Alberto M., Carandente, Orazio, Pontiroli, Antonio E., Melino, Gerry, Marchetti, Piero, Lauro, Renato, Sesti, Giorgio, and Folli, Franco

Published
2001

88. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)

Author

Le Grazie Cristina, Pontiroli Antonio E, Giorda Carlo B, Bardini Gianluca, and Rotella Carlo M

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM). Methods Adult patients with T2DM and CHD (N = 93) on a stable dose of simvastatin 20 mg with LDL-C ≥ 2.6 mmol/L (100 mg/dL) and ≤ 4.1 mmol/L (160 mg/dL) were randomized to ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 10/20 mg) or simvastatin 40 mg for 6 weeks. Percent change in LDL-C, high-density lipoprotein cholesterol, and triglycerides was assessed. Results EZ + simva 10/20 mg produced a significantly greater change from treated baseline compared with simvastatin 40 mg in LDL-C (-32.2% vs -20.8%; p < 0.01) and total cholesterol (-20.6% vs -13.2%; p < 0.01). A greater proportion of patients achieved LDL-C < 2.6 mmol/L with EZ + simva 10/20 mg than with simvastatin 40 mg, but this was not statistically significant (78.4% vs 60%; odds ratio = 2.81; p = 0.052). Changes in high-density lipoprotein cholesterol and triglycerides were similar between treatments. Both treatments were generally well-tolerated. Conclusions These results demonstrate that EZ + simva 10/20 mg may provide a superior alternative for LDL-C lowering vs doubling the dose of simvastatin to 40 mg in hyperlipidemic patients with T2DM and CHD. In addition, the combination therapy may provide an alternative treatment for patients who require further LDL-C reduction than they can achieve with simvastatin 20 mg alone.

Published
2010
Full Text
View/download PDF

89. Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters

Author

Folli Franco, Micheletto Giancarlo, Frigè Francesca, Veronelli Annamaria, Laneri Marco, Pontiroli Antonio E, Adami Gianfranco, and Scopinaro Nicola

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Bariatric surgery is able to improve glucose and lipid metabolism, and cardiovascular function in morbid obesity. Aim of this study was to compare the long-term effects of malabsorptive (biliary pancreatic diversion, BPD), and restrictive (laparoscopic gastric banding, LAGB) procedures on metabolic and cardiovascular parameters, as well as on metabolic syndrome in morbidly obese patients. Methods 170 patients studied between 1989 and 2001 were called back after a mean period of 65 months. 138 patients undergoing BPD (n = 23) or LAGB (n = 78), and control patients (refusing surgery and treated with diet, n = 37) were analysed for body mass index (BMI), blood glucose, cholesterol, and triglycerides, blood pressure, heart rate, and ECG indexes (QTc, Cornell voltage-duration product, and rate-pressure-product). Results After a mean 65 months period, surgery was more effective than diet on all items under evaluation; diabetes, hypertension, and metabolic syndrome disappeared more in surgery than in control patients, and new cases appeared only in controls. BPD was more effective than LAGB on BMI, on almost all cardiovascular parameters, and on cholesterol, not on triglyceride and blood glucose. Disappearance of diabetes, hypertension, and metabolic syndrome was similar with BPD and with LAGB, and no new cases were observed. Conclusion These data indicate that BPD, likely due to a greater BMI decrease, is more effective than LAGB in improving cardiovascular parameters, and similar to LAGB on metabolic parameters, in obese patients. The greater effect on cholesterol levels is probably due to the different mechanism of action.

Published
2009
Full Text
View/download PDF

92. Hyperinsulinemia decreases second-phase but not first-phase arginine-induced insulin release in humans

Author

Piatti, Piero M., Pontiroli, Antonio E., Caumo, Andrea, Santambrogio, Giovanni, Monti, Lucilla D., Costa, Sabrina, Garbetta, Francesca, Baruffaldi, Laura, Cobelli, Claudio, and Pozza, Guido

Subjects
Insulin -- Physiological aspects, Arginine -- Physiological aspects, Health, Physiological aspects
Abstract

The aim of this study was to investigate the effect of hyperinsulinemia on the first and second phase of arginine-induced insulin release in humans. Seven healthy subjects underwent three studies [...]

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results